Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GD9E
|
|||
| Drug Name |
GAP T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Baylor College of Medicine
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glypican-3 (GPC3) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Glypican pathway | |||
| Glypican 3 network | ||||
| Reactome | A tetrasaccharide linker sequence is required for GAG synthesis | |||
| HS-GAG degradation | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.